MedTrace Logo

A Functional Magnetic Resonance Imaging (fMRI) Study in Overweight and Obese Men (0000-103)

NCT00914212 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2015-10-12

No results posted yet for this study

Summary

This study will determine whether BOLD-fMRI can be used to probe hunger and satiety states in healthy overweight or obese men and also whether fasted/fed fMRI signals can be modulated by sibutramine.

Conditions

Interventions

DRUG

Placebo

Single dose placebo to sibutramine in two of three treatment periods.

DRUG

Comparator: sibutramine

Single dose sibutramine 30 mg (2 x 15 mg) in one of three treatment periods.

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2009-08-31
Completion
2009-08-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00914212 on ClinicalTrials.gov